trastuzumab,pertuzumab
roche
['bcsm', 'breast']
results from the phergain trial at #asco23 suggest that patients with early breast cancer may benefit from dual her2 blockade alone without chemo: #bcsm #ascodailynews 
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ≠ endorse.